Since the induction of PAI-1 occurs during the moderate stage before COVID-19 patients require intensive care, the evaluation of PAI-1 would help in designing better thromboprophylaxis to limit the disease severity [95]. This evidence concerns the gene SERPINE1 and COVID-19.